Articles MINT: opportunities in 'frontier' markets? The prospects for pharma in the MINT emerging countries of Mexico, Indonesia, Nigeria and Turkey.
Views & Analysis New frontiers in pharma: is ‘MINT’ the next ‘BRIC’? MINT countries: what the opportunities may be for pharma and healthcare.
News FDA approves higher Wegovy dose via 4th priority voucher The US FDA has approved a fourth product via its new National Priority Voucher Programme -- a 7.2 mg dose of Novo Nordisk's weight loss drug Wegovy (semaglutide), to be marketed as Wegovy HD.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
